Compare RL & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RL | UTHR |
|---|---|---|
| Founded | 1967 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 20.3B |
| IPO Year | 1997 | 1999 |
| Metric | RL | UTHR |
|---|---|---|
| Price | $357.87 | $507.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | $376.46 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 708.7K | 464.8K |
| Earning Date | 02-05-2026 | 10-29-2025 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ 28.75 | 16.08 |
| EPS | 13.54 | ★ 26.38 |
| Revenue | ★ $7,570,600,000.00 | $3,128,400,000.00 |
| Revenue This Year | $12.94 | $13.64 |
| Revenue Next Year | $5.02 | $5.78 |
| P/E Ratio | $26.45 | ★ $19.23 |
| Revenue Growth | 12.32 | ★ 13.50 |
| 52 Week Low | $176.61 | $266.98 |
| 52 Week High | $380.00 | $519.99 |
| Indicator | RL | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 61.16 |
| Support Level | $360.34 | $498.76 |
| Resistance Level | $380.00 | $519.99 |
| Average True Range (ATR) | 8.99 | 11.19 |
| MACD | -1.99 | 0.18 |
| Stochastic Oscillator | 32.53 | 69.81 |
Founded by designer Ralph Lauren (current executive chairman and chief creative officer) in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle merchandise in North America, Europe, and Asia. Best known for its iconic polo shirts, its products also include other types of apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.